I enjoyed talking to Beth Snyder Bulik of Endpoints News recently about the impact of lawsuits on biopharmaceutical companies' brands. Pharma's day in court: Is the daily downpour of lawsuits giving pharma companies a bad rep? – Endpoints News endpts.com/pharmas-day-in…

Interesting story by ⁦Sumathi Reddy⁩ of the ⁦The Wall Street Journal⁩ on research looking into what’s driving long COVID. Root Cause of Long Covid Sought tinyurl.com/2m64gnlz

.Adam Feuerstein ✡️ out with his biotech scorecard for the fourth quarter: 14 stock-moving events to watch statnews.com/2022/09/30/bio… via STAT

The future of drug design are “smart” biologics - proteins, usually antibodies, engineered to deliver activity in the right place at the right time It will be these agents, not gene or cell therapies or gene editing that dominate the 2040 medicine cabinet

.Jared S. Hopkins of the The Wall Street Journal with a nice scoop.

Fascinating discussion with Matthew Herper of STAT and Dr Lloyd Minor of Stanford on life sciences collaboration. #STATinNYC

The latest on Alzheimer’s disease being discussed with @jasonkarlawish and Damian Garde of STAT. #STATinNYC

Looking forward to seeing everyone at the first in-person JPM conference in a few years. #JPM23

As we prepare for #JPM23 next week, I'm pleased to share the results of our 3rd annual healthcare & life sciences survey. As always, this could not have been accomplished without a tremendous team effort.

The question, when we put Brad Loncar on stage with Sy Mukherjee (the-sy-guy.bsky.social) between two indie rock bands at #AltJPM Sunday… Suit/tie or band T? So looking forward to hearing Brad’s predictions for #JPM23

Welcome, Lauren!

No flight delays can stop this team! FTI Consulting FTI Consulting Strategic Communications #JPM23 #TeamFTI

.John Carroll talking key 2023 industry themes with Catalent CEO. #JPM23

.⁦Jared S. Hopkins⁩ looks at the near- and long-term implications of the IRA. A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them. tinyurl.com/2pw3p55n

According to a recent FTI Consulting survey, most #healthcare and #lifesciences companies have a positive 2023 outlook but are concerned about the economy. I shed light on some of these fears via PRWeekUS. bit.ly/3YmP159

Interesting piece from Lizzy Lawrence of STAT on the medical device pathway to clearances.

Biotech Funding: Times Are Tough, Maybe For The Better. lifescivc.com/2023/04/biotec…

Have a look at this piece from Kyle LaHucik on deals on the first day of #JPM24.

Hello world, I've been laid off from Business Insider. I'm very sad and scared right now, and I've got pets to feed! If you know of any editing gigs, please send them my way. I also have some experience in grant writing, and a master's in public health if that helps 🤷‍♀️

You know you're a JPM veteran when.... You're at dinner with a group of biotech / Wall Street folks and you're reminiscing about Sam Waksal's Imclone "mea culpa" presentation in 2002 -- because you were all there to see it live.